Geode Capital Management LLC Raises Position in Xencor, Inc. (NASDAQ:XNCR)

Geode Capital Management LLC lifted its stake in Xencor, Inc. (NASDAQ:XNCR) by 12.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,634,876 shares of the biopharmaceutical company’s stock after purchasing an additional 179,526 shares during the quarter. Geode Capital Management LLC’s holdings in Xencor were worth $37,578,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV lifted its position in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 813 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,337 shares in the last quarter. Sanctuary Advisors LLC grew its holdings in Xencor by 5.3% in the fourth quarter. Sanctuary Advisors LLC now owns 28,263 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 1,432 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Xencor by 13.0% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,940 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 1,723 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on XNCR shares. StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Wells Fargo & Company lowered their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.38.

Xencor Stock Up 6.7 %

Shares of NASDAQ:XNCR opened at $9.54 on Wednesday. The firm has a 50 day simple moving average of $12.75 and a 200-day simple moving average of $18.94. Xencor, Inc. has a twelve month low of $7.16 and a twelve month high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $672.21 million, a PE ratio of -2.98 and a beta of 0.90.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $52.79 million during the quarter, compared to analysts’ expectations of $17.14 million. On average, equities analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.